Results 101 to 110 of about 10,600 (216)
Recombinant Zoster Vaccination Among US Veterans Receiving Immunosuppressive Medications
JAMA Network OpenThis cross-sectional study investigates rates of recombinant zoster vaccination among US veterans receiving immunosuppressive medications before and after expanded indications for younger adults who are immunocompromised.
Abada, Sharon +6 more
openaire +2 more sources
Het Rijksvaccinatieprogramma in Nederland : Surveillance en ontwikkelingen in 2014-2015 [PDF]
, 2017 In Nederland is de vaccinatiegraad binnen het Rijksvaccinatieprogramma (RVP) hoog, waardoor weinig mensen de ziekten krijgen waartegen zij worden ingeënt.
de Melker HE +1 more
core
Zika virus: New clinical syndromes and its emergence in the western hemisphere [PDF]
, 2016 Zika virus (ZIKV) had remained a relatively obscure flavivirus until a recent series of outbreaks accompanied by unexpectedly severe clinical complications brought this virus into the spotlight as causing an infection of global public health concern.
Brazilian Medical Genetics Society–Zika Embryopathy Task Force +9 more
core +3 more sources
Биопрепараты: Профилактика, диагностика, лечениеINTRODUCTION. Varicella zoster virus remains a serious threat to public health and is a significant burden on the health system due to treatment costs. Vaccination coverage against varicella zoster (VZ) and herpes zoster (HZ) remains low for a number of
A. V. Zotova, O. A. Svitich
doaj +1 more source
At the current time, the field of vaccinology remains empirical in many respects. Vaccine development, vaccine immunogenicity, and vaccine efficacy have, for the most part, historically been driven by an empiric "isolate-inactivate-inject" paradigm.
core
Development Of Gene Deleted Recombinant Pseudorabies Virus [PDF]
, 2004 The glycoprotein E (gE) and thymidine kinase (TK) genes are virulence-associated genes of pseudorabies virus (PrV). The study conducted was to shut down the gE gene from an established local TK defective (TK¯) PrV strain (TK¯gE+PrV).
Alauddin, Zeenathul Nazariah
core
Recombinant Zoster Vaccination and Risk of Postherpetic Neuralgia or Zoster Ophthalmicus
JAMA Network OpenThis cohort study uses health plan data to investigate whether recombinant zoster vaccination is associated with a reduced risk of postherpetic neuralgia or zoster ophthalmicus.
Zerbo, Ousseny +9 more
openaire +1 more source
Immune responses to zoster vaccines
Human Vaccines & Immunotherapeutics, 2019 There are two licensed herpes zoster vaccines. One is a live vaccine (ZVL) based on an attenuated varicella-zoster virus (VZV). The other is a recombinant vaccine (RZV) based on the VZV glycoprotein E (gE) combined with AS01B, a multicomponent adjuvant ...
Myron J Levin, Adriana Weinberg
doaj +1 more source
Recommended immunization schedule for adults aged 19 years or older, United States, 2018 [PDF]
In February 2018, the Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2018 became effective, as recommended by the Advisory Committee on Immunization Practices (ACIP) and approved by the Centers for Disease Control and
core
Trained Immunity Generated by the Recombinant Zoster Vaccine
Abstract Trained immunity may play a role in vaccine-induced protection against infections. We showed that the highly efficacious recombinant VZV-gE zoster vaccine (RZV) generated trained immunity in monocytes, natural killer (NK) cells, and dendritic cells (DCs) and that the less efficacious live zoster vaccine did not.
Adriana Weinberg +5 more
openaire +2 more sources